Page 26 - Biocon

Biocon's Q4 net profit jumps 250% to Rs 361 crore on exceptional income

Amount of Rs 268 crore, allocated for research earlier, was shown as income after inking pact for rh insulin with Mexico-based firm

Biocon expects more filings this year for biosimilars, drugs

Q4 profit up 79% to Rs 361 crore; invests more on R&D

Street confidence rises on Biocon's insulin biosimilars

With expected filings of four insulin products in the current financial year, analysts have started upgrading their earnings estimates for the company

Biocon nears 52-week high on heavy volumes

The stock up 9% to Rs 533 on the BSE, trading close its 52-week high of Rs 544 touched on January 5.

Biocon to co-develop and produce recombinant insulin for US market

Ties up with Mexico's PiSA for the insulin to tap the $2-billion US market